F D C Ltd

Stage 4 · Declining · week 5

As of 16 Oct 2026, F D C is in Stage 4 — declining, a downtrend, in week 5 (since 11 Sep 2026). It closed at ₹356, 21.7% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.6% of stocks are in Stage 2.

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. More about the company

₹356.3
+1.38% today
₹5,800 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is FDC early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-21.7%
₹321.1 lo₹454.8 hi
21.7% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 5
1w13w26w
Week 5 — early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-4.5%
200 DMA: ₹373.2 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
0.46x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -1.2% vs MA50 -7.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+1.7%
3M
-15.2%
6M
+0.1%
YTD
-12.5%
1Y
-19.7%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 15w
S2 51w
S4 15w
S4 27w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 4w → S2 51w → S3 10w → S4 15w → S1 9w → S2 8w → S3 9w → S4 27w → S1 7w → S2 5w → S3 3w → S4 5w current
Total tracked: 169 weeks across 13 stage runs.
Scan Membership
Prop Scan
Latest: 2026-07-31
Breakout Watch
Latest: 2026-07-14
16 appearances in last 60 days. First seen: 2025-07-21.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S4
Wk 5 · Vol 0.46x
2026-10-15S4
Wk 5 · Vol 1.15x
2026-10-14S4
Wk 5 · Vol 0.51x
2026-10-13S4
Wk 5 · Vol 0.44x
2026-10-12S4
Wk 4 · Vol 0.70x
2026-10-09S4
Wk 4 · Vol 0.37x
2026-10-08S4
Wk 4 · Vol 0.56x
2026-10-07S4
Wk 4 · Vol 0.41x
2026-10-06S4
Wk 4 · Vol 0.55x
2026-10-05S4
Wk 3 · Vol 0.44x
2026-10-01S4
Wk 3 · Vol 0.53x
2026-09-30S4
Wk 3 · Vol 0.50x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹346.7
200 DMA
₹373.2
52W High
₹454.8
52W Low
₹321.1
5D Low
₹338.5
Resistance levels (recent highs)
20d High
₹362.8
60d High
₹417.1
120d High
₹434.3
250d High
₹454.8
Next resistance
+1.8%
to 20d High
Ask the Market AI about FDCAsk →
P/E (TTM)
32.3
Forward 18.4
Earnings Growth (YoY)
-23.7%
Revenue +0.1%
Dividend Yield
2.48%
P/B 2.9
About this companyHealth Care· Pharmaceuticals

FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.